Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Autoimmune Diseases of the Nervous System

ClinicalTrials.gov lists 4,435 trials for Autoimmune Diseases of the Nervous System or a narrower condition beneath it. Biogen has the most among industry and government lead sponsors, with 161.

MeSH D020274 Nervous System Diseases C10 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 286 Phase 1/2 Phase 1/2 128 Phase 2 Phase 2 447 Phase 2/3 Phase 2/3 72 Phase 3 Phase 3 419 Phase 4 Phase 4 246 Not applicable Not applicable 1,427 Observational Observational 1,393 Phase 1 Phase 1 286 Phase 1/2 Phase 1/2 128 Phase 2 Phase 2 447 Phase 2/3 Phase 2/3 72 Phase 3 Phase 3 419 Phase 4 Phase 4 246 Not applicable Not applicable 1,427 Observational Observational 1,393

Trials per phase

1 more section with rows

120 of the 4,435 trials are tagged with Autoimmune Diseases of the Nervous System itself; the rest are tagged with a narrower condition beneath it.

Get the Autoimmune Diseases of the Nervous System report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Autoimmune Diseases of the Nervous System trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 309

1990: 1 trials (Phase 2 1) 1991: 2 trials (Not applicable 1, Phase 3 1) 1992: 2 trials (Observational 1, Phase 3 1) 1993: 2 trials (Not applicable 1, Phase 3 1) 1994: 3 trials (Not applicable 1, Phase 4 1, Phase 2 1) 1995: 5 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 1 1) 1996: 5 trials (Observational 2, Phase 3 2, Phase 1 1) 1997: 3 trials (Other 1, Phase 2 1, Phase 1 1) 1998: 3 trials (Phase 2 1, Phase 1/2 1, Phase 1 1) 1999: 11 trials (Observational 1, Phase 4 2, Phase 3 3, Phase 2 4, Phase 1/2 1) 2000: 4 trials (Observational 2, Not applicable 1, Phase 3 1) 2001: 18 trials (Not applicable 1, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 2) 2002: 30 trials (Observational 4, Phase 4 2, Phase 3 12, Phase 2 8, Phase 1/2 3, Phase 1 1) 2003: 44 trials (Observational 6, Not applicable 3, Phase 4 8, Phase 3 5, Phase 2 14, Phase 1/2 3, Phase 1 5) 2004: 47 trials (Observational 8, Not applicable 3, Phase 4 10, Phase 3 7, Phase 2/3 5, Phase 2 9, Phase 1/2 3, Phase 1 2) 2005: 58 trials (Other 1, Observational 14, Not applicable 5, Phase 4 4, Phase 3 14, Phase 2/3 1, Phase 2 15, Phase 1/2 1, Phase 1 3) 2006: 78 trials (Observational 15, Not applicable 11, Phase 4 5, Phase 3 23, Phase 2/3 1, Phase 2 15, Phase 1/2 4, Phase 1 4) 2007: 76 trials (Observational 21, Not applicable 8, Phase 4 5, Phase 3 16, Phase 2/3 3, Phase 2 14, Phase 1/2 2, Phase 1 7) 2008: 85 trials (Observational 27, Not applicable 7, Phase 4 9, Phase 3 15, Phase 2/3 1, Phase 2 14, Phase 1/2 4, Phase 1 8) 2009: 95 trials (Observational 24, Not applicable 15, Phase 4 9, Phase 3 9, Phase 2/3 4, Phase 2 20, Phase 1/2 5, Phase 1 9) 2010: 125 trials (Observational 35, Not applicable 17, Phase 4 9, Phase 3 15, Phase 2/3 2, Phase 2 22, Phase 1/2 8, Phase 1 17) 2011: 120 trials (Observational 34, Not applicable 27, Phase 4 12, Phase 3 14, Phase 2/3 5, Phase 2 18, Phase 1/2 3, Phase 1 7) 2012: 144 trials (Observational 53, Not applicable 32, Phase 4 13, Phase 3 12, Phase 2/3 3, Phase 2 16, Phase 1/2 6, Phase 1 9) 2013: 159 trials (Observational 40, Not applicable 42, Phase 4 19, Phase 3 17, Phase 2/3 2, Phase 2 18, Phase 1/2 11, Phase 1 10) 2014: 190 trials (Observational 55, Not applicable 63, Phase 4 17, Phase 3 17, Phase 2/3 1, Phase 2 18, Phase 1/2 8, Phase 1 11) 2015: 183 trials (Observational 51, Not applicable 53, Phase 4 18, Phase 3 16, Phase 2/3 4, Phase 2 20, Phase 1/2 6, Phase 1 15) 2016: 165 trials (Observational 45, Not applicable 65, Phase 4 12, Phase 3 13, Phase 2/3 1, Phase 2 15, Phase 1/2 3, Phase 1 11) 2017: 191 trials (Observational 61, Not applicable 73, Phase 4 11, Phase 3 14, Phase 2/3 4, Phase 2 12, Phase 1/2 6, Phase 1 10) 2018: 222 trials (Observational 62, Not applicable 104, Phase 4 7, Phase 3 20, Phase 2/3 1, Phase 2 15, Phase 1/2 4, Phase 1 9) 2019: 267 trials (Observational 91, Not applicable 99, Phase 4 8, Phase 3 24, Phase 2/3 3, Phase 2 25, Phase 1/2 4, Phase 1 13) 2020: 251 trials (Observational 95, Not applicable 91, Phase 4 10, Phase 3 17, Phase 2/3 5, Phase 2 15, Phase 1/2 4, Phase 1 14) 2021: 304 trials (Observational 128, Not applicable 98, Phase 4 11, Phase 3 22, Phase 2/3 5, Phase 2 19, Phase 1/2 4, Phase 1 17) 2022: 277 trials (Observational 96, Not applicable 105, Phase 4 10, Phase 3 24, Phase 2/3 7, Phase 2 21, Phase 1/2 5, Phase 1 9) 2023: 309 trials (Observational 109, Not applicable 150, Phase 4 5, Phase 3 13, Phase 2/3 1, Phase 2 15, Phase 1/2 3, Phase 1 13) 2024: 307 trials (Observational 107, Not applicable 117, Phase 4 9, Phase 3 18, Phase 2/3 8, Phase 2 19, Phase 1/2 5, Phase 1 24) 2025: 305 trials (Observational 91, Not applicable 123, Phase 4 7, Phase 3 22, Phase 2/3 2, Phase 2 26, Phase 1/2 7, Phase 1 27)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 308
2025 305
2024 307
2023 309
2022 277
2021 304
2020 251
2019 267
2018 222
2017 191

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 350 trials starting in 2026 and about 330 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 429 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 2,646 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Autoimmune Diseases of the Nervous System trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 286
Phase 1/2 128
Phase 2 447
Phase 2/3 72
Phase 3 419
Phase 4 246
Not applicable 1,427
Observational 1,393
Expanded access 17

How many Autoimmune Diseases of the Nervous System trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 234
Recruiting 576
Enrolling by invitation 61
Active, not recruiting 199
Available 3

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Autoimmune Diseases of the Nervous System trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Biogen 161
Novartis Pharmaceuticals 101
Merck KGaA, Darmstadt, Germany 49
Bayer 47
Hoffmann-La Roche 46

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Autoimmune Diseases of the Nervous System? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Dimethyl Fumarate 60
METHYLPREDNISOLONE 47
RITUXIMAB 45
Efgartigimod 22

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SC interferon beta-1a 81
Ocrelizumab SC 73
fingolimob (FTY) 56
SC interferon beta-1b 50
natalizumab SC 49

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Autoimmune Diseases of the Nervous System trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Multiple sclerosis relapse 1,787 88
Multiple Sclerosis Relapse 664 29
Urinary tract infection 428 95
Pneumonia 421 119
MULTIPLE SCLEROSIS RELAPSE 282 12

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Autoimmune Diseases of the Nervous System? (55)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Immunoadsorption is equally effective as plasma exchange in paediatric neuroimmunological disorders - A retrospective multicentre study. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2025 Yes
Relevance of Kappa and Lambda Free Light Chains in Autoimmune Astrocytopathy Associated With Anti-GFAP Antibodies. Annals of clinical and translational neurology 2025 Yes
Microglial Activation Imaging Using <sup>18</sup>F-DPA-714 PET/MRI for Detecting Autoimmune Encephalitis. Radiology 2024 Yes
Autoimmune Encephalitis-Misdiagnosis, Misconceptions, and How to Avoid Them. JAMA neurology 2023 Yes
Immunoadsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseases. Journal of clinical apheresis 2022 Yes

Showing 5 of 55 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (9)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages